{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"2"}],"units":"Participants"}],"description":"Patients with event(s) of dose-limiting toxicity","groups":[{"description":"Part 1: Patients received a starting dose of 30 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.\n\nPatients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG000","title":"Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QD"},{"description":"Part 1: Patients received a starting dose of 60 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.\n\nPatients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG001","title":"Experimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QD"},{"description":"Part 1: Patients received a starting dose of 90 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.\n\nPatients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG002","title":"Experimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QD"},{"description":"Part 1: Patients received a starting dose of 135 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.\n\nPatients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG003","title":"Experimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QD"},{"description":"Part 1: Patients received a starting dose of 200 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.\n\nPatients received avapritinib in continuous 28 day cycles until discontinuation. .","id":"OG004","title":"Experimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QD"},{"description":"Part 1: Patients received a starting dose of 300 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.\n\nPatients received avapritinib in continuous 28 day cycles until discontinuation. Patients that received at least one dose of avapritinib were included in the Part 2 analysis.","id":"OG005","title":"Experimental: Part 1 Avapritinib (Formerly BLU-285) 300 mg QD"},{"description":"Part 1: Patients received a starting dose of 400 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.\n\nPatients received avapritinib in continuous 28 day cycles until discontinuation.\n\nPatients that received at least one dose of avapritinib were included in the Part 2 analysis.","id":"OG006","title":"Experimental: Part 1 Avapritinib (Formerly BLU-285) 400 mg QD"},{"description":"Part 1: Patients received a starting dose of 600 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.\n\nPatients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG007","title":"Experimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QD"}],"paramType":"NUMBER","populationDescription":"Patients that completed Part 1 or had a DLT","reportingStatus":"POSTED","timeFrame":"Cycle 1 (28 days) of treatment","title":"Part 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Avapritinib","type":"PRIMARY","unitOfMeasure":"patients with event(s) of dose-limiting"}